In growth hormone (GH) secretagogue research, the combination of CJC-1295 (No DAC) and Ipamorelin is universally recognized as the gold standard for restoring natural, youthful endocrine signaling. However, significant confusion exists regarding nomenclature, pharmacokinetic profiles, and receptor targets. Understanding the scientific evidence behind CJC-1295 no DAC ipamorelin reveals how dual GHRH and ghrelin-receptor signaling generates synergistic, physiological GH pulses without desensitizing pituitary somatotrophs.
⚡ Quick Summary: CJC-1295 (No DAC) + Ipamorelin Evidence
Quick Answer: Combining CJC-1295 (No DAC / Mod GRF 1-29) with Ipamorelin pairs a Growth Hormone Releasing Hormone (GHRH) analogue with a selective Growth Hormone Secretagogue Receptor (GHSR-1a) agonist. When administered together, they trigger a supra-additive, synergistic pulse of natural growth hormone that is 2–5x greater than either peptide alone. Crucially, the "No DAC" formulation has a ~30-minute half-life, which preserves the body's natural pulsatile rhythm and prevents pituitary bleed, cortisol spikes, or prolactin elevation.
| Compound Component | Receptor Target | Biological Half-Life | Physiological Role in Blend |
|---|---|---|---|
| CJC-1295 (No DAC / Mod GRF) | GHRH Receptor (Pituitary) | ~30 Minutes | Amplifies the amplitude of pituitary GH release pulses |
| Ipamorelin | GHSR-1a (Ghrelin Receptor) | ~2 Hours | Inhibits somatostatin, triggering clean, selective GH exocytosis |
| CJC-1295 WITH DAC | GHRH Receptor + Serum Albumin | 6 to 8 Days | Continuous, non-pulsatile elevation; not suitable for daily cycling |
The Science of Synergy: Why 1 + 1 = 5 in GH Signaling
In standard endocrinology, pituitary growth hormone release is governed by a delicate dual-control mechanism: a "gas pedal" and a "brake pedal." Administering either compound alone produces modest results, but pairing them creates true biological synergy:
1. CJC-1295 Steps on the Gas
As a 29-amino-acid synthetic GHRH mimetic, Mod GRF 1-29 binds to GHRH receptors on pituitary somatotrophs, activating adenylate cyclase and cAMP to stimulate GH synthesis and release.
2. Ipamorelin Cuts the Brakes
Ipamorelin activates the ghrelin receptor (GHSR-1a), increasing intracellular calcium while suppressing somatostatin (growth hormone inhibiting hormone), allowing the pituitary to empty its stored GH reserve.
3. Zero Off-Target Endocrine Spill
Unlike older secretagogues (like GHRP-2 or GHRP-6), Ipamorelin is exquisitely selective: it triggers powerful GH pulses with zero significant stimulation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin.
Explore Verified Growth Hormone Signaling Synergy
Experience the research standard in dual-pathway secretagogue protocols. Review analytical purity and laboratory-verified specifications for CJC-1295 (No DAC) + Ipamorelin.
Shop CJC-1295 (No DAC) + Ipamorelin →DAC vs. No DAC: Why Product Identity Dictates the Evidence
One of the most persistent traps in peptide research is applying published data from CJC-1295 with DAC to CJC-1295 without DAC:
- The DAC Modification: The Drug Affinity Complex (DAC) adds a reactive maleimide bioconjugate that covalently binds to circulating albumin in the bloodstream. This extends the half-life from 30 minutes to over 6 to 8 days (Teichman et al., 2006).
- The Clinical Difference: While CJC-1295 with DAC produces continuous, flat GH elevation ("GH bleed"), physiological endocrinology relies on natural, rhythmic peaks and troughs. Continuous exposure desensitizes pituitary receptors and disrupts insulin sensitivity.
- Why "No DAC" Wins for Research: CJC-1295 No DAC (tetrasubstituted Modified GRF 1-29) mimics the body's natural nocturnal pulses. It elevates circulating GH for a sharp 60-to-90-minute window, allowing pituitary receptors to rest, reset, and avoid somatotroph exhaustion. For an exhaustive comparison, read: CJC-1295 Guide: DAC vs. No DAC, Mechanisms & Protocols.
Synergistic Research Pairings & GHRH Comparisons
Depending on your experimental protocol—whether evaluating lipolysis, lean muscle accrual, or recovery—compare the dual blend against related secretagogue systems:
- Standalone Secretagogue Studies: To isolate ghrelin receptor kinetics without GHRH co-stimulation, explore pure Ipamorelin. Review our complete guide: Ipamorelin Explained: Mechanism & Research.
- Visceral Adiposity & GHRH Analogs: Compare Mod GRF 1-29 with Tesamorelin, an FDA-studied GHRH analogue specifically researched for visceral adipose clearance and lipid profiling. Read: Tesamorelin Guide: Mechanisms, Visceral Fat Protocols & Lab Standards.
- Deep-Dive Blend Dynamics: For advanced protocol structures and night-time dosing schedules, consult our comprehensive resource: The CJC-1295 + Ipamorelin Complete Research Guide.
Standardized 2.0 mL Reconstitution Math for Research Vials
The combination of CJC-1295 (No DAC) + Ipamorelin is typically compounded in balanced 1:1 mass ratios (such as a 10 mg total vial containing 5 mg CJC-1295 No DAC and 5 mg Ipamorelin). When reconstituted with 2.0 mL of Pfizer Hospira Bacteriostatic Water:
Concentration Formula: Mass (mg) ÷ Solvent Volume (mL) = Concentration (mg/mL). In a 10 mg (5mg/5mg) vial brought to 2.0 mL total volume, each 1.0 mL contains 2.5 mg CJC-1295 No DAC and 2.5 mg Ipamorelin (5 mg/mL total blend concentration).
| Draw Volume (U-100 Syringe) | Total Blend Mass | CJC-1295 (No DAC) Yield | Ipamorelin Yield |
|---|---|---|---|
| 4 Units (0.04 mL) | 200 mcg | 100 mcg (0.10 mg) | 100 mcg (0.10 mg) |
| 8 Units (0.08 mL) | 400 mcg | 200 mcg (0.20 mg) | 200 mcg (0.20 mg) |
| 10 Units (0.10 mL) | 500 mcg | 250 mcg (0.25 mg) | 250 mcg (0.25 mg) |
| 20 Units (0.20 mL) | 1,000 mcg | 500 mcg (0.50 mg) | 500 mcg (0.50 mg) |
Eliminate unit-to-microgram arithmetic mistakes before preparing research draws with our free Peptide Calculator.
Hardware Selection: Moving Beyond Disposable Syringes
Secretagogue research relies on consistent, multi-week dosing schedules. Upgrading your lab delivery hardware protects fragile compound bonds and ensures absolute volumetric repeatability:
- Reusable Injection Pens: Instead of puncturing rubber stoppers daily and squinting at plastic barrel lines, transfer your reconstituted blend into 3mL Injection Pen Glass Cartridges and pair with the V3 Reusable Injection Pen. The mechanical lead-screw ensures precise, audibly indexed micro-dosing with zero needle-hub fluid dead space.
- Precision Manual Syringes: If manual draws are preferred, draw with surgical-grade Easy Touch 31G U-100 Syringes with 0.5 mL barrels. The ultra-fine 31-gauge needle glides cleanly through septums without tearing or coring rubber stoppers.
- Light-Blocking Case Protection: Unprotected reconstituted peptides degrade under ambient light and refrigerator door vibrations. Store your active vials upright inside the Compact 4-Slot Case or the high-capacity 10-Slot Peptide Vial Case. For mobile protocols, carry supplies inside the insulated Compact Peptide Travel Case.
Protocol Builder & Tracking Tools
Maintain complete laboratory chain-of-custody across your CJC/Ipamorelin cycles:
- Protocol Structuring: Schedule daily pulses, rest cycles, and reconstitution volumes inside the Protocol Builder.
- Observation Logging: Record sleep architecture markers, IGF-1 serum readings, and beyond-use dates inside the Protocol Tracker Tool.
Frequently Asked Questions
Why is CJC-1295 No DAC often referred to as "Mod GRF 1-29"?
Technically, "CJC-1295" originally designated the long-acting molecule formulated with DAC. When scientists developed the identical tetrasubstituted peptide without the Drug Affinity Complex, its correct biochemical name became "Modified GRF 1-29." In colloquial research vernacular, the two terms are used interchangeably.
Why do researchers emphasize administering this blend in a fasted state?
Elevated blood glucose and circulating insulin blunt the pituitary's release of growth hormone. For optimal experimental pulses, laboratory protocols typically schedule administration either first thing in the morning or before bedtime, at least 2 hours after food intake.
Does Ipamorelin stimulate appetite like GHRP-6?
No. While GHRP-6 strongly stimulates the appetite-inducing neuro-circuitry of ghrelin, Ipamorelin is a selective second-generation secretagogue that triggers GH release without causing intense, uncontrollable hunger pangs.
Related Reading & Scientific References
- CJC-1295 Guide: DAC vs No DAC, Mechanisms & Protocols
- CJC-1295 + Ipamorelin Complete Research Guide
- Ipamorelin Explained: Mechanism & Research
- Teichman et al. (2006): Prolonged Stimulation of Growth Hormone and IGF-1 by CJC-1295 (PubMed)
By coordinating GHRH receptor activation with selective ghrelin-pathway secretagogue stimulation, CJC-1295 (No DAC) + Ipamorelin delivers the pinnacle of physiological growth hormone signaling. Choosing the No-DAC variant ensures safe, pulsatile secretion that respects natural pituitary rhythms while elevating systemic IGF-1 recovery pathways.
← View all peptide guides, research & protocols in our Blog Archive
